This site is intended for healthcare professionals
Latest industry news
  • Home
  • /
  • News
  • /
  • 2024
  • /
  • 4
  • /
  • Acorda Therapeutics files for voluntary bankruptcy

Acorda Therapeutics files for voluntary bankruptcy

Read time: 1 mins
Published:3rd Apr 2024

Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to Inbrija, Ampyra, and Fampyra for $185 million.

Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, headquartered in Frankfurt am Main, Germany. To facilitate an orderly sale process, and in an effort to maximize the value for the Company's assets through a competitive auction process, with Merz serving as the "stalking horse" bidder, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.